Literature DB >> 19675450

Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.

Andrea Grin1, Frances P O'Malley, Anna Marie Mulligan.   

Abstract

The presence of atypical or usual epithelial proliferations within papillary breast lesions complicates their interpretation on core biopsy. We evaluated the combination of estrogen receptor (ER) and cytokeratin 5 (CK5) as an aid in the distinction of usual duct hyperplasia from atypical proliferations in this setting. Core biopsies from 185 papillary lesions were reviewed and of these, 82 cases were selected for immunohistochemical study based on the presence of an epithelial proliferation between the fibrovascular cores. Fifty-two cases were used as the test set and 30 cases, with subsequent surgical excision, were used as the validation set. The epithelial proliferation was evaluated for staining intensity and percentage of positive cells using CK5 and ER. Expression of both CK5 and ER was significantly different in nonatypical lesions when compared with atypical lesions (P<0.0001). Nonatypical lesions typically showed an ER-low/CK5-high profile and atypical lesions showed an ER-high/CK5-low profile with ER-high expression defined as diffuse strong staining in >90% of cells. CK5-high expression was defined as a mosaic pattern of staining in >20% of cells and CK5-low as absent or staining in <20% of cells. On the basis of their staining profile, 29 of the 30 validation cases were correctly classified using the excision specimen as the gold standard. Patterns and extent of ER and CK5 staining, when used together, are valuable adjunct stains to differentiate usual duct hyperplasia from atypical proliferations within papillary lesions on core biopsy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675450     DOI: 10.1097/PAS.0b013e3181aec446

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.

Authors:  Naoki Kanomata; Rin Yamaguchi; Junichi Kurebayashi; Takuya Moriya
Journal:  Med Mol Morphol       Date:  2019-05-28       Impact factor: 2.309

Review 2.  Papillary carcinoma of the breast: an overview.

Authors:  Sumanta Kumar Pal; Sean K Lau; Laura Kruper; Uzoamaka Nwoye; Carlos Garberoglio; Ravi K Gupta; Benjamin Paz; Lalit Vora; Eduardo Guzman; Avo Artinyan; George Somlo
Journal:  Breast Cancer Res Treat       Date:  2010-06-04       Impact factor: 4.872

3.  Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ.

Authors:  Gary Tozbikian; Edi Brogi; Christina E Vallejo; Dilip Giri; Melissa Murray; Jeffrey Catalano; Cristina Olcese; Kimberly J Van Zee; Hannah Yong Wen
Journal:  Int J Surg Pathol       Date:  2016-08-04       Impact factor: 1.271

4.  Histological analysis of benign breast imaging reporting and data system categories 4c and 5 breast lesions in imaging study.

Authors:  Min Jung Kim; Dokyung Kim; WooHee Jung; Ja Seung Koo
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

Review 5.  Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy.

Authors:  Edi Brogi; Melissa Krystel-Whittemore
Journal:  Mod Pathol       Date:  2020-10-26       Impact factor: 7.842

Review 6.  Papillary neoplasms of the breast-reviewing the spectrum.

Authors:  Timothy Kwang Yong Tay; Puay Hoon Tan
Journal:  Mod Pathol       Date:  2021-01-18       Impact factor: 7.842

7.  Follow-up of breast papillary lesion on core needle biopsy: experience in African-American population.

Authors:  He Wang; Patricia Tsang; Cyril D'Cruz; Kevin Clarke
Journal:  Diagn Pathol       Date:  2014-04-24       Impact factor: 2.644

8.  Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis.

Authors:  Cecilia W Huo; Mark Waltham; Christine Khoo; Stephen B Fox; Prue Hill; Shou Chen; Grace L Chew; John T Price; Chau H Nguyen; Elizabeth D Williams; Michael Henderson; Erik W Thompson; Kara L Britt
Journal:  Breast Cancer Res       Date:  2016-10-25       Impact factor: 6.466

9.  Ductal carcinoma in situ: what the pathologist needs to know and why.

Authors:  Anita Bane
Journal:  Int J Breast Cancer       Date:  2013-02-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.